Warning of cardiac risk with new MS drug

Safety regulators have issued fresh warnings about the new oral multiple sclerosis drug fingolimod, advising doctors against using it in certain patients with cardiovascular disease.

The US Food and Drug Administration said Monday it “remained concerned about the cardiovascular effects of fingolimod (Gilenya) after the first dose”, and recommended the drug be contraindicated in patients with recent major cardiovascular events or stroke.